Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain

PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse LiverSignificance

(2015) Annie Demers et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition

(2015) Nathalie Bergeron et al.   CIRCULATION

Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other

(2015) Chutikarn Butkinaree et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

(2015) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

GRP94 Regulates Circulating Cholesterol Levels through Blockade of PCSK9-Induced LDLR Degradation

(2015) Steve Poirier et al.   Cell Reports

The Hypercholesterolemia-Risk Gene SORT1 Facilitates PCSK9 Secretion

(2014) Camilla Gustafsen et al.   Cell Metabolism

PCSK9

(2014) Nabil G. Seidah et al.   CIRCULATION RESEARCH

The Epigenetic Drug 5-Azacytidine Interferes with Cholesterol and Lipid Metabolism

(2014) Steve Poirier et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society

(2013) B. G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

Characterization of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Trafficking Reveals a Novel Lysosomal Targeting Mechanism via Amyloid Precursor-like Protein 2 (APLP2)

(2013) Rachel M. DeVay et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts

(2013) My-Anh Nguyen et al.   JOURNAL OF LIPID RESEARCH

PCSK9-mediated degradation of the LDL receptor generates a 17 kDa C-terminal LDL receptor fragment

(2013) Kristian Tveten et al.   JOURNAL OF LIPID RESEARCH

Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia

(2012) Marianne Abifadel et al.   ATHEROSCLEROSIS

easyFRAP: an interactive, easy-to-use tool for qualitative and quantitative analysis of FRAP data

(2012) Maria Anna Rapsomaniki et al.   BIOINFORMATICS

The M2 Module of the Cys-His-rich Domain (CHRD) of PCSK9 Protein Is Needed for the Extracellular Low-density Lipoprotein Receptor (LDLR) Degradation Pathway

(2012) Yascara Grisel Luna Saavedra et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Annexin A2 Is a Natural Extrahepatic Inhibitor of the PCSK9-Induced LDL Receptor Degradation

(2012) Nabil G. Seidah et al.   PLoS One

Novel Loss-of-Function PCSK9 Variant Is Associated with Low Plasma LDL Cholesterol in a French-Canadian Family and with Impaired Processing and Secretion in Cell Culture

(2011) J. Mayne et al.   CLINICAL CHEMISTRY

Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH

(2011) Paola Lo Surdo et al.   EMBO REPORTS

Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors

(2011) Øystein L. Holla et al.   JOURNAL OF LIPID RESEARCH

A Proprotein Convertase Subtilisin-like/Kexin Type 9 (PCSK9) C-terminal Domain Antibody Antigen-binding Fragment Inhibits PCSK9 Internalization and Restores Low Density Lipoprotein Uptake

(2010) Yan G. Ni et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Effects of the Prosegment and pH on the Activity of PCSK9

(2010) Suzanne Benjannet et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A Two-step Binding Model of PCSK9 Interaction with the Low Density Lipoprotein Receptor

(2010) Taichi Yamamoto et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Constructing and Exploiting the Fluorescent Protein Paintbox (Nobel Lecture)

(2009) Roger Y. Tsien   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Hepatocyte Nuclear Factor 1α Plays a Critical Role inPCSK9Gene Transcription and Regulation by the Natural Hypocholesterolemic Compound Berberine

(2009) Hai Li et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells

(2009) Markey C. McNutt et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation

(2009) Steve Poirier et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Molecular basis of PCSK9 function

(2008) Gilles Lambert et al.   ATHEROSCLEROSIS

PCSK9 is phosphorylated by a Golgi casein kinase-like kinase ex vivo and circulates as a phosphoprotein in humans

(2008) Thilina Dewpura et al.   FEBS Journal

Structural and Biochemical Characterization of the Wild Type PCSK9-EGF(AB) Complex and Natural Familial Hypercholesterolemia Mutants

(2008) Matthew J. Bottomley et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Annexin A2 Is a C-terminal PCSK9-binding Protein That Regulates Endogenous Low Density Lipoprotein Receptor Levels

(2008) Gaétan Mayer et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Molecular basis for LDL receptor recognition by PCSK9

(2008) H. J. Kwon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor

(2008) D.-W. Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA